Testagen (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Injections are given once daily subcutaneously, with sites rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy. At 10 mg/mL one unit is 100 mcg, so 100 mcg is 1 unit, 150 mcg is 1.5 units, 200 mcg is 2 units, and 300 mcg is 3 units. Every dose in the protocol is therefore a very small draw of 1 to 3 units, which is 0.01 to 0.03 mL, and a 30 unit or 50 unit insulin syringe is specified for any administration under 10 units; at this concentration every dose in the course falls under that threshold, so a 100 unit barrel is the wrong instrument here. No dose approaches the 100 unit ceiling of a single injection, so nothing in this protocol splits across two sites. The master sheet sets no time of day for the injection, only that it happens once per day.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: the course opens at 100 mcg daily, which is 1 unit at 10 mg/mL, before any step up.
• Weeks 3 to 4: the first titration step takes the daily dose to 150 mcg, which is 1.5 units.
• Weeks 5 to 8: the working dose of 200 mcg daily, 2 units, holds for four weeks.
• Weeks 9 to 12: the top of the range at 250 to 300 mcg daily, 2.5 to 3 units, closes a standard course.
• Weeks 13 to 16: an optional extension holds the top of the range. The master sheet describes no taper and no outcome timeline, because no human trial data exist.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 100 mcg = 1 unit, 150 mcg = 1.5 units, 200 mcg = 2 units, 300 mcg = 3 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F), protected from light; avoid freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 2.0 mL per 20 mg vial, one reconstituted vial holds about 200 units of solution, far more than a full course draws down at 1 to 3 units per day, so refrigerated in-use time rather than remaining volume is what retires a vial. Reconstitute one vial at a time rather than opening both at the start.

Supplies Needed

Planning is based on a daily protocol of 8 to 16 weeks with gradual titration, which works out to roughly 0.7 to 2.1 mg per week across the 100 to 300 mcg range.

Peptide Vials (Testagen, 20 mg vial):

• An 8 week course uses about 14 mg, which is about 1 vial of the 20 mg presentation; a 12 week course uses about 25 mg, about 2 vials; a 16 week course uses about 36 mg, still about 2 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes, one per day, with 30 unit or 50 unit barrels preferred since every dose sits between 1 and 3 units.
• 8 weeks: 56 syringes. 12 weeks: 84 syringes. 16 weeks: 112 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 20 mg vial takes 2.0 mL, so one 10 mL bottle of bacteriostatic water covers 5 vials, well beyond the 1 to 2 vials an 8 to 16 week course requires.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 14 swabs per week.
• 8 weeks: 112 swabs. 12 weeks: 168 swabs. 16 weeks: 224 swabs (three 100 count boxes).

Important Notes

Practical considerations for consistency and safety.

• New sterile insulin syringes are used for every injection and disposed of in a sharps container.
• Injection sites are rotated across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy.
• Injection is slow and steady, with a wait of a few seconds before the needle is withdrawn. Subcutaneous injections are not aspirated.
• Daily dose and site rotation are documented so the titration stays consistent across an 8 to 16 week course.
• Injection volumes are very low. At 10 mg/mL the opening dose of 100 mcg is a single unit, so a 30 unit or 50 unit syringe is needed for readable precision, since a 100 unit barrel cannot resolve a half unit step reliably.
• Regulatory Note: Testagen is not an approved drug for human therapeutic use and is supplied for research purposes only, not for human consumption. No human clinical trials exist, so there is no human safety or efficacy record behind it. The master sheet does not record a WADA classification for this compound.

How This Works

Testagen (Lys-Glu-Asp-Gly) belongs to a class of short bioregulatory peptides derived from anterior pituitary extracts. Preclinical research in avian models demonstrates that this tetrapeptide can normalize thyroid hormone levels in hypophysectomized subjects and modulate endocrine signaling along the pituitary-gonadal axis. These peptides are hypothesized to act through gene-regulatory mechanisms influencing hormone synthesis and secretion, the same proposed route described across the wider Khavinson bioregulator class. No human clinical trials exist, so the mechanism stands as a preclinical and in vitro inference rather than a demonstrated human effect.

Benefits & Side Effects

Observations from the published record.

• Preclinical studies suggest normalization of thyroid hormone parameters in hypophysectomized models.
• Research indicates potential modulation of male reproductive hormones via pituitary pathways.
• No published human safety or efficacy data exist, so the side-effect profile in humans remains unknown.
• Occasional mild injection-site reactions such as redness or itch may occur with subcutaneous administration.
• The evidence base is confined to preclinical and in vitro work, and no human dose-response data exist to anchor the 100 to 300 mcg daily range.

Lifestyle Factors

Complementary strategies for best outcomes.

• A balanced, nutrient-dense diet supporting endocrine health is the baseline complementary factor alongside the daily course.
• Regular physical activity supports hormonal balance and is listed as a complementary factor throughout the protocol.
• Quality sleep of 7 to 9 hours supports the endogenous hormone rhythms the pituitary-gonadal axis runs on.
• Stress management through mindfulness or comparable techniques reduces cortisol interference with endocrine signaling.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Effects of hypophyseal Lys-Glu-Asp-Gly peptide on immunity, hemostasis, and thyroid function (PubMed).
2. Khavinson VK et al. Peptide Regulation of Gene Expression: A Systematic Review.